Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: A case study in depression

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 863-871

  Russu, A ^a   Marostica, E ^a   De Nicolao, G ^a   Hooker, A C ^b   Poggesi, I ^c,d   Gomeni, R ^e,f   Zamuner, S ^g  

^a UNIVERSITY OF PAVIA   (Italy)

^b UPPSALA UNIVERSITY   (Sweden)

^c GSK   (Italy)

^d Advanced Modeling and Simulation   (Italy)

^e GLAXOSMITHKLINE   (United States)

^f Alleantis   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; INFORMATION PROCESSING; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; HUMANS; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN;

EID: 84859983690     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.322     Document Type: Article

References (26)

1. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56-62 (1960).
2. Santen, G., Gomeni, R., Danhof, M. & Della Pasqua, O. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J. Psychiatr. Res. 42, 1000-1009 (2008).
3. Cosson, V. & Gomeni, R. Modeling placebo response in depression using a mechanistic longitudinal model approach. Population Approach Group in Europe (PAGE) 14th Meeting, Abstract 818. 〈http://www.page-meeting.org/?abstract= 818〉 (2005).
4. Mould, D.R., Denman, N.G. & Duffull, S. Using disease progression models as a tool to detect drug effect. Clin. Pharmacol. Ther. 82, 81-86 (2007).
5. Gomeni, R., Lavergne, A. & Merlo-Pich, E. Modeling placebo response in depression trials using a longitudinal model with informative dropout. Eur. J. Pharm. Sci. 36, 4-10 (2009).
6. Shang, E.Y. et al. Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. J. Pharmacokinet. Pharmacodyn. 36, 63-80 (2009).
7. .Holford, N., Ma, S.C. & Ploeger, B.A. Clinical trial simulation: a review. Clin. Pharmacol. Ther. 88, 166-182 (2010).
8. Merlo-Pich, E. & Gomeni, R. Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs. Clin. Pharmacol. Ther. 84, 378-384 (2008).
9. Gomeni, R. & Merlo-Pich, E. Bayesian modeling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br. J. Clin. Pharmacol. 63, 595-613 (2007).
10. Nucci, G., Gomeni, R. & Poggesi, I. Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. Expert Opin. Drug Discov. 4, 837-856 (2009).
11. Santen, G., Danhof, M. & Della Pasqua, O. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. J. Psychiatr. Res. 42, 1189-1197 (2008).
12. Holford, N., Li, J., Benincosa, L. & Birath, M. Population Disease Progress Models for the Time Course of HAMD Score in Depressed Patients Receiving Placebo in Anti-Depressant Clinical Trials. Population Approach Group in Europe (PAGE) 11th Meeting, Abstract 311. 〈http://www.page-meeting.org/? abstract=311〉 (2002).
13. A merican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn, Text Revision. 〈http://psych.org/MainMenu/ Research/DSMIV.aspx〉 (1994).
14. Khan, A., Khan, S.R., Walens, G., Kolts, R. & Giller, E.L. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28, 552-557 (2003).
15. Hu, C. & Sale, M.E. A joint model for nonlinear longitudinal data with informative dropout. J. Pharmacokinet. Pharmacodyn. 30, 83-103 (2003).
16. Hu, C., Szapary, P.O., Yeilding, N. & Zhou, H. Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. J. Pharmacokinet. Pharmacodyn. 38, 237-260 (2011).
17. Molenberghs, G. et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics 5, 445-464 (2004).
18. Wang, J.W. & Lee, E.T. Statistical Methods for Survival Data Analysis. 3rd edn. (Wiley, Hoboken, NJ, 2003).
19. Cartwright, M.E. et al. Proof of concept: a PhRMA position paper with recommendations for best practice. Clin. Pharmacol. Ther. 87, 278-285 (2010).
20. Lunn, D.J., Thomas, A., Best, N. & Spiegelhalter, D. WinBUGS - A Bayesian modeling framework: concepts, structure and extensibility. Stat. Comput. 10, 325-337 (2000).
21. Spiegelhalter, D., Best, N.G., Carlin, B.P., Van der Linde, A. Bayesian measures of model complexity and fit (with discussion). J. R. Statist. Soc. B 64, 583-639 (2002).
22. Frame, B., Miller, R. & Hutmacher, M.M. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. J. Pharmacokinet. Pharmacodyn. 36, 565-584 (2009).
23. Lalovic, B., Hutmacher, M., Frame, B. & Miller, R. Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder. J. Clin. Pharmacol. 51, 706-718 (2011).
24. Rief, W. et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf. 32, 1041-1056 (2009).
25. Trivedi, M.H. et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 34, 73-82 (2004).
26. R Development Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria). 〈http://www.R-project.org〉 2009.